2.33
VolitionRX Ltd Borsa (VNRX) Ultime notizie
VolitionRx Limited 2025 Annual Report: Executive Compensation, Director Ownership, and Corporate Governance Insights - Minichart
VNRX Stock Price, Quote & Chart | VOLITIONRX LTD (NYSEARCA:VNRX) - ChartMill
VolitionRX Limited (VNRX) Investment Case | Q4 2025: Earnings UnderperformEV/EBITDA - Newser
CEO pay, board changes and reverse split at VolitionRx (NYSE: VNRX) - Stock Titan
VolitionRx (VNRX) Achieves Breakthrough in Sepsis Detection with New Test - GuruFocus
Volition Announces Breakthrough Finger-Prick Detection of Nucleosomes; Expanding Global Market Potential for Sepsis Testing - Barchart
VolitionRx Limited Announces Amendment to Certificate of Incorporation in April 2026 8-K Filing - Minichart
VolitionRx (NYSE: VNRX) implements 1-for-20 reverse stock split - Stock Titan
DISCLOSED: 5 Stocks Congress Just Bought (PC6HZG2Kcg) - Fathom Journal
VolitionRX | 8-K: Current report - Moomoo
VNRX Should I Buy - Intellectia AI
VolitionRx receives NYSE American compliance plan approval By Investing.com - Investing.com Australia
VolitionRx receives NYSE American compliance plan approval - Investing.com
VolitionRx Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
VolitionRx (NYSE: VNRX) wins NYSE American time to fix listing - Stock Titan
VolitionRx shares stay on NYSE as exchange accepts compliance plan - Stock Titan
D Boral Capital downgrades VolitionRx (VNRX) - MSN
VolitionRx launches online shop for recombinant nucleosomes By Investing.com - Investing.com Australia
VNRX Downgraded by D. Boral Capital -- Rating Changed to Hold - GuruFocus
VolitionRx Ltd stock (US92852X1037): Does its blood-testing tech unlock real diagnostic upside? - AD HOC NEWS
D. Boral Capital downgrades VolitionRX stock rating on reverse split By Investing.com - Investing.com South Africa
D. Boral Capital Downgrades VolitionRX(VNRX.US) to Hold Rating - Moomoo
After building for 10 years, Volition puts nucleosomes up for sale online - Stock Titan
VolitionRx Limited Files Form 8-K With SEC Detailing Company Information and Compliance Data - Minichart
VolitionRx Ltd stock (US92852X1037): Is its blood-testing breakthrough strong enough to unlock inves - AD HOC NEWS
VolitionRx Sets One-for-Twenty Reverse Stock Split - The Globe and Mail
VolitionRx (VNRX) to execute 1-for-20 reverse stock split on April 28, 2026 - Stock Titan
Volition approves 1-for-20 reverse stock split effective April 28, 2026 - TradingView
VolitionRx Ltd stock (US92852X1037): Why does its blood-testing innovation matter more now for U.S. - AD HOC NEWS
H.C. Wainwright cuts VolitionRX stock price target to $1 on share count - Investing.com Australia
VolitionRx Earnings Call: Breakthroughs Amid Funding Strain - TipRanks
VolitionRx Limited (VNRX) stock price, news, quote and history - Yahoo Finance UK
VNRX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
VolitionRX (VNRX) FY2025 Earnings: Q4 EPS and Revenue Not Disclo - GuruFocus
VolitionRX Is Maintained at Buy by HC Wainwright & Co. - Moomoo
VolitionRx Limited (AMEX:VNRX) Q4 2025 Earnings Call Transcript - Insider Monkey
VolitionRX Q4 Earnings Call Highlights - Defense World
VolitionRX Ltd (VNRX) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
VolitionRX Ltd (VNRX) Q4 2025 Earnings Call Highlights: Strong R - GuruFocus
VolitionRx: Robust Revenue Growth and Promising Capture-Seq Data Support Buy Rating Despite Dilution-Driven Target Cut - TipRanks
VolitionRX (VNRX) Sees Target Price Cut Despite Maintained Buy R - GuruFocus
VolitionRx Limited (VNRX) 8-K SEC Filing March 31, 2026: Company Details, Address, and Stock Information - Minichart
VolitionRx (NYSE: VNRX) wins approval for major share issue and reverse split - Stock Titan
Earnings call transcript: VolitionRx Q4 2025 reveals mixed financial results By Investing.com - Investing.com South Africa
Earnings call transcript: VolitionRx Q4 2025 reveals mixed financial results - Investing.com
Q4 2025 VolitionRX Ltd Earnings Call Transcript - GuruFocus
VolitionRx : Corporate Presentation April 2026 - marketscreener.com
VolitionRX's Nu.Q Cancer Reimbursement Decision in Q4 2026 Could Unlock Commercial Licensing Momentum Amid Dilution Risks - Bitget
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):